BPaL Research: A Snapshot
Access to the latest treatment innovations is a human right.
3,611 patients in more than 33 countries accessed TB Alliance products for highly drug-resistant TB alone in 2021. We cannot afford to stop until our treatments are available to everyone who needs them.
TB Market Research
A major historical challenge in tackling childhood TB has been understanding the scope of the problem.Learn More
Pathway to Patients: Charting the Dynamics of the Global TB Drug Market, was the first comprehensive analysis of how today's TB drugs reach patients on a global scale.Learn More
TB Alliance sought opinions on attributes that key decision-makers want in new regimens, including safety, efficacy, drug delivery, side effect profiles, and cost.Learn More
TB Alliance investigated health systems to understand the regimen change process, in order to accelerate and maximize the uptake of new products.Learn More
TB treatment is widely understood to be a public sector responsibility. However, our research found that in some countries the volume of TB drugs sold in the private sector is equal to or greater than the volume sold in the public sector.Learn More